January 30, 2020 – Federal Register Recent Federal Regulation Documents

Reader Aids
Document Number: FR-2020-01-30-ReaderAids
Type: Reader Aids
Date: 2020-01-30
Sunshine Act Meetings; National Science Board
Document Number: 2020-01911
Type: Notice
Date: 2020-01-30
Agency: National Science Foundation, Agencies and Commissions
Facilitating the Use of WIPO's ePCT System To Prepare International Applications for Filing With the United States Receiving Office
Document Number: 2020-01765
Type: Proposed Rule
Date: 2020-01-30
Agency: Department of Commerce, Patent and Trademark Office
The United States Patent and Trademark Office (USPTO or Office) is proposing to amend the foreign filing license rules to facilitate use of ePCT (a World Intellectual Property Organization (WIPO) online web-based service) to prepare an international application for filing with the USPTO in its capacity as a Receiving Office under the Patent Cooperation Treaty (PCT). ePCT offers many benefits to users, including real time up-to-date validation features to help users properly complete the PCT Request. ePCT resides on WIPO's servers abroad and is accessed via an internet browser on the user's system. While the current foreign filing license rules would authorize the export of technical data to ePCT for purposes of preparing an international application for filing in a foreign PCT Receiving Office, the current rules do not authorize the export of technical data to ePCT for purposes of preparing an international application for filing with the USPTO as a Receiving Office. The USPTO is thus proposing to amend the foreign filing license rules to provide that a foreign filing license from the USPTO would authorize the export of technical data abroad for purposes relating to the use of ePCT to prepare an international application for filing with the USPTO in its capacity as a Receiving Office under the PCT.
Parts and Accessories Necessary for Safe Operation; Application for an Exemption From Robert Bosch LLC and Mekra Lang North America LLC
Document Number: 2020-01763
Type: Notice
Date: 2020-01-30
Agency: Federal Motor Carrier Safety Administration, Department of Transportation
The Federal Motor Carrier Safety Administration (FMCSA) requests public comment on an application for exemption from Robert Bosch LLC and Mekra Lang North America LLC to allow motor carriers to operate commercial motor vehicles (CMVs) equipped with the company's CV [Commercial Vehicle] Digital Mirror System installed as an alternative to the two rear-vision mirrors required by the Federal Motor Carrier Safety Regulations (FMCSR).
Hours of Service of Drivers: McKee Foods Transportation, LLC, Application for Exemption
Document Number: 2020-01762
Type: Notice
Date: 2020-01-30
Agency: Federal Motor Carrier Safety Administration, Department of Transportation
FMCSA announces that it has received an application from McKee Foods Transportation, LLC (MFT) for a renewal of its exemption from the hours-of-service (HOS) regulation pertaining to the use of a sleeper berth. The exemption renewal would allow MFT team drivers to take the equivalent of 10 consecutive hours off duty by splitting sleeper berth time into two periods totaling 10 hours, provided neither of the two periods is less than 3 hours. MFT currently holds an exemption for the period March 27, 2015, through March 27, 2020. FMCSA requests public comment on MFT's application for exemption. The application for a renewal is available for review in the docket referenced at the beginning of this notice.
Qualification of Drivers; Exemption Applications; Hearing
Document Number: 2020-01758
Type: Notice
Date: 2020-01-30
Agency: Federal Motor Carrier Safety Administration, Department of Transportation
FMCSA announces its decision to renew exemptions for four individuals from the hearing requirement in the Federal Motor Carrier Safety Regulations (FMCSRs) for interstate commercial motor vehicle (CMV) drivers. The exemptions enable these hard of hearing and deaf individuals to continue to operate CMVs in interstate commerce.
National Center for Health Statistics (NCHS), ICD-10 Coordination and Maintenance (C&M) Committee Meeting
Document Number: 2020-01756
Type: Notice
Date: 2020-01-30
Agency: Centers for Disease Control and Prevention, Department of Health and Human Services
The Centers for Disease Control and Prevention, National Center for Health Statistics (NCHS), Classifications and Public Health Data Standards Staff, announces the following meeting of the ICD-10 Coordination and Maintenance (C&M) Committee meeting. This meeting is open to the public, limited only by the space available. The meeting room accommodates approximately 240 people. We will be broadcasting the meeting live via Webcast at https:// www.cms.gov/live/.
Agency Information Collection Activities; Submission for OMB Review; Comment Request; Multiple Internal Revenue Service Information Collection Requests
Document Number: 2020-01754
Type: Notice
Date: 2020-01-30
Agency: Department of the Treasury
The Department of the Treasury will submit the following information collection requests to the Office of Management and Budget (OMB) for review and clearance in accordance with the Paperwork Reduction Act of 1995, on or after the date of publication of this notice. The public is invited to submit comments on these requests.
Defense Science Board; Notice of Federal Advisory Committee Meeting
Document Number: 2020-01753
Type: Notice
Date: 2020-01-30
Agency: Department of Defense, Office of the Secretary
The DoD is publishing this notice to announce that the following Federal Advisory Committee meeting of the Defense Science Board (DSB) will take place.
Notice Pursuant to the National Cooperative Research and Production Act of 1993-CHEDE-8
Document Number: 2020-01752
Type: Notice
Date: 2020-01-30
Agency: Antitrust Division, Department of Justice
Meeting of the Mobile Sources Technical Review Subcommittee
Document Number: 2020-01749
Type: Notice
Date: 2020-01-30
Agency: Environmental Protection Agency
Pursuant to the Federal Advisory Committee Act notice is hereby given that the Mobile Sources Technical Review Subcommittee (MSTRS) will meet on March 31, 2020. The MSTRS is a subcommittee under the Clean Air Act Advisory Committee. This is an open meeting. The meeting will include discussion of current topics and presentations about activities being conducted by EPA's Office of Transportation and Air Quality. The preliminary agenda for the meeting and any notices about change in venue will be posted on the Subcommittee's website: https://www2.epa.gov/caaac/mobile-sources-technical-review-sub committee- mstrs-caaac. MSTRS listserv subscribers will receive notification when the agenda is available on the Subcommittee website. To subscribe to the MSTRS listserv, send an email to mccubbin.courtney@epa.gov.
Information Collection: NRC Form 850, Request for Contractor Assignment(s)
Document Number: 2020-01746
Type: Notice
Date: 2020-01-30
Agency: Nuclear Regulatory Commission, Agencies and Commissions
The U.S. Nuclear Regulatory Commission (NRC) has recently submitted a request for renewal of an existing collection of information to the Office of Management and Budget (OMB) for review. The information collection is entitled, NRC Form 850, ``Request for Contractor Assignment(s).''
National Institute of Dental & Craniofacial Research; Notice of Closed Meetings
Document Number: 2020-01744
Type: Notice
Date: 2020-01-30
Agency: Department of Health and Human Services, National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Document Number: 2020-01743
Type: Notice
Date: 2020-01-30
Agency: Department of Health and Human Services, National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Document Number: 2020-01742
Type: Notice
Date: 2020-01-30
Agency: Department of Health and Human Services, National Institutes of Health
National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Closed Meetings
Document Number: 2020-01741
Type: Notice
Date: 2020-01-30
Agency: Department of Health and Human Services, National Institutes of Health
National Institute on Alcohol Abuse and Alcoholism; Notice of Closed Meeting
Document Number: 2020-01740
Type: Notice
Date: 2020-01-30
Agency: Department of Health and Human Services, National Institutes of Health
National Eye Institute; Notice of Closed Meeting
Document Number: 2020-01739
Type: Notice
Date: 2020-01-30
Agency: Department of Health and Human Services, National Institutes of Health
National Eye Institute; Notice of Closed Meeting
Document Number: 2020-01738
Type: Notice
Date: 2020-01-30
Agency: Department of Health and Human Services, National Institutes of Health
National Cancer Institute; Notice of Closed Meetings
Document Number: 2020-01737
Type: Notice
Date: 2020-01-30
Agency: Department of Health and Human Services, National Institutes of Health
National Cancer Institute Amended; Notice of Meeting
Document Number: 2020-01736
Type: Notice
Date: 2020-01-30
Agency: Department of Health and Human Services, National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Document Number: 2020-01735
Type: Notice
Date: 2020-01-30
Agency: Department of Health and Human Services, National Institutes of Health
Information Collection Being Reviewed by the Federal Communications Commission Under Delegated Authority
Document Number: 2020-01734
Type: Notice
Date: 2020-01-30
Agency: Federal Communications Commission, Agencies and Commissions
As part of its continuing effort to reduce paperwork burdens, and as required by the Paperwork Reduction Act (PRA), the Federal Communications Commission (FCC or Commission) invites the general public and other Federal agencies to take this opportunity to comment on the following information collection. Comments are requested concerning: Whether the proposed collection of information is necessary for the proper performance of the functions of the Commission, including whether the information shall have practical utility; the accuracy of the Commission's burden estimate; ways to enhance the quality, utility, and clarity of the information collected; ways to minimize the burden of the collection of information on the respondents, including the use of automated collection techniques or other forms of information technology; and ways to further reduce the information collection burden on small business concerns with fewer than 25 employees. The FCC may not conduct or sponsor a collection of information unless it displays a currently valid Office of Management and Budget (OMB) control number. No person shall be subject to any penalty for failing to comply with a collection of information subject to the PRA that does not display a valid OMB control number.
Information Collection Being Reviewed by the Federal Communications Commission
Document Number: 2020-01733
Type: Notice
Date: 2020-01-30
Agency: Federal Communications Commission, Agencies and Commissions
As part of its continuing effort to reduce paperwork burdens, and as required by the Paperwork Reduction Act of 1995 (PRA), the Federal Communications Commission (FCC or Commission) invites the general public and other Federal agencies to take this opportunity to comment on the following information collections. Comments are requested concerning: Whether the proposed collection of information is necessary for the proper performance of the functions of the Commission, including whether the information shall have practical utility; the accuracy of the Commission's burden estimate; ways to enhance the quality, utility, and clarity of the information collected; ways to minimize the burden of the collection of information on the respondents, including the use of automated collection techniques or other forms of information technology; and ways to further reduce the information collection burden on small business concerns with fewer than 25 employees. The FCC may not conduct or sponsor a collection of information unless it displays a currently valid Office of Management and Budget (OMB) control number. No person shall be subject to any penalty for failing to comply with a collection of information subject to the PRA that does not display a valid OMB control number.
Meeting of the Community Preventive Services Task Force (CPSTF)
Document Number: 2020-01732
Type: Notice
Date: 2020-01-30
Agency: Centers for Disease Control and Prevention, Department of Health and Human Services
The CDC within the HHS announces the next meeting of the CPSTF on February 12, 2020.
Agency Information Collection Activities; Submission for OMB Review; Comment Request; Multiple Fiscal Service Information Collection Requests
Document Number: 2020-01731
Type: Notice
Date: 2020-01-30
Agency: Department of the Treasury
The Department of the Treasury will submit the following information collection requests to the Office of Management and Budget (OMB) for review and clearance in accordance with the Paperwork Reduction Act of 1995, on or after the date of publication of this notice. The public is invited to submit comments on these requests.
Certain Fabricated Structural Steel From Mexico: Final Affirmative Countervailing Duty Determination
Document Number: 2020-01723
Type: Notice
Date: 2020-01-30
Agency: Department of Commerce, International Trade Administration
The Department of Commerce (Commerce) determines that countervailable subsidies are being provided to producers and exporters of certain fabricated structural steel (fabricated structural steel) from Mexico. The period of investigation is January 1, 2018 through December 31, 2018.
Certain Fabricated Structural Steel From Mexico: Final Determination of Sales at Less Than Fair Value
Document Number: 2020-01722
Type: Notice
Date: 2020-01-30
Agency: Department of Commerce, International Trade Administration
The Department of Commerce (Commerce) determines that certain fabricated structural steel (fabricated structural steel) from Mexico is being, or is likely to be, sold in the United States at less than fair value (LTFV). The period of investigation (POI) is January 1, 2018 through December 31, 2018. The final dumping margins of sales at LTFV are shown in the ``Final Determination'' section of this notice.
Certain Fabricated Structural Steel From the People's Republic of China: Final Affirmative Countervailing Duty Determination
Document Number: 2020-01721
Type: Notice
Date: 2020-01-30
Agency: Department of Commerce, International Trade Administration
The Department of Commerce (Commerce) determines that countervailable subsidies are being provided to producers and/or exporters of certain fabricated structural steel (fabricated structural steel) from the People's Republic of China (China). The period of investigation is January 1, 2018 through December 31, 2018.
Certain Fabricated Structural Steel From the People's Republic of China: Final Affirmative Determination of Sales at Less Than Fair Value
Document Number: 2020-01720
Type: Notice
Date: 2020-01-30
Agency: Department of Commerce, International Trade Administration
The Department of Commerce (Commerce) determines that certain fabricated structural steel (fabricated structural steel) from the People's Republic of China (China) is being, or is likely to be, sold in the United States at less than fair value (LTFV). The period of investigation is July 1, 2018 through December 31, 2018. The final dumping margins of sales at LTFV are listed below in the ``Final Determination'' section of this notice.
Certain Fabricated Structural Steel From Canada: Final Negative Countervailing Duty Determination
Document Number: 2020-01719
Type: Notice
Date: 2020-01-30
Agency: Department of Commerce, International Trade Administration
The Department of Commerce (Commerce) determines that countervailable subsidies are not being provided to producers and exporters of certain fabricated structural steel (fabricated structural steel) from Canada. The period of investigation is January 1, 2018 through December 31, 2018.
Certain Fabricated Structural Steel From Canada: Final Determination of Sales at Less Than Fair Value
Document Number: 2020-01718
Type: Notice
Date: 2020-01-30
Agency: Department of Commerce, International Trade Administration
The Department of Commerce (Commerce) determines that certain fabricated structural steel (fabricated structural steel) from Canada is being, or is likely to be, sold in the United States at less than fair value (LTFV). The period of investigation (POI) is January 1, 2018 through December 31, 2018. The final dumping margins of sales at LTFV are listed below in the ``Final Determination'' section of this notice.
Agency Information Collection Activities; Submission for OMB Review; Comment Request; Multiple Tax and Trade Bureau Information Collection Requests
Document Number: 2020-01716
Type: Notice
Date: 2020-01-30
Agency: Department of the Treasury
The Department of the Treasury will submit the following information collection requests to the Office of Management and Budget (OMB) for review and clearance in accordance with the Paperwork Reduction Act of 1995, on or after the date of publication of this notice. The public is invited to submit comments on these requests.
Agency Information Collection Activities; Comment Request; Application and Employment Certification for Public Service Loan Forgiveness
Document Number: 2020-01715
Type: Notice
Date: 2020-01-30
Agency: Department of Education
In accordance with the Paperwork Reduction Act of 1995, ED is proposing a revision of an existing information collection.
Agency Information Collection Activities: Submission to OMB for Review and Approval; Public Comment Request; Nurse Corps Loan Repayment Program, OMB No. 0915-0140 Revision
Document Number: 2020-01713
Type: Notice
Date: 2020-01-30
Agency: Department of Health and Human Services, Health Resources and Services Administration
In compliance with the Paperwork Reduction Act of 1995, HRSA submitted an Information Collection Request (ICR) to the Office of Management and Budget (OMB) for review and approval. Comments submitted during the first public review of this ICR will be provided to OMB. OMB will accept further comments from the public during the review and approval period. OMB may act on HRSA's ICR only after the 30-day comment period for this Notice has closed.
Notice of Intent To Grant Partially Exclusive License
Document Number: 2020-01712
Type: Notice
Date: 2020-01-30
Agency: National Aeronautics and Space Administration, Agencies and Commissions
NASA hereby gives notice of its intent to grant a partially exclusive patent license in the United States to practice the inventions described and claimed in U.S. Patent No. 8,167,204 B2 for an invention entitled ``Wireless Damage Location Sensing System,'' NASA Case Number LAR-17593-1; U.S. Patent No. 7,086,593 B2 for an invention entitled ``Magnetic Field Response Measurement Acquisition System,'' NASA Case Number LAR-16908-1; U.S. Patent No. 7,159,774 B2 for an invention entitled ``Magnetic Field Response Measurement Acquisition System,'' NASA Case Number LAR-17280-1; U.S. Patent No. 8,430,327 B2 for an invention entitled ``Wireless Sensing System Using Open-Circuit, Electrically-Conductive Spiral-Trace Sensor,'' NASA Case Number LAR- 17294-1; U.S. Patent No. 8,042,739 B2 for an invention entitled ``Wireless Tamper Detection Sensor and Sensing System,'' NASA Case Number LAR-17444-1; U.S. Patent No. 7,814,786 B2 for an invention entitled ``Wireless Sensing System for Non-Invasive Monitoring of Attributes of Contents in a Container,'' NASA Case Number LAR-17488-1; U.S. Patent No. 8,673,649 B2 for an invention entitled ``Wireless Chemical Sensor and Sensing Method for Use Therewith,'' NASA Case Number LAR-17579-1; U.S. Patent No. 9,329,149 B2 for an invention entitled ``Wireless Chemical Sensor and Sensing Method for Use Therewith,'' NASA Case Number LAR-17579-2; U.S. Patent No. 9,733,203 B2 for an invention entitled ``Wireless Chemical Sensing Method,'' NASA Case Number LAR-17579-3; U.S. Patent No. 8,179,203 B2 for an invention entitled ``Wireless Electrical Device Using Open-Circuit Elements Having No Electrical Connections,'' NASA Case Number LAR-17711-1; and U.S. Patent No. 10,193,228 B2 for an invention entitled ``Antenna for Near Field Sensing and Far Field Transceiving,'' NASA Case Number LAR- 18400-1, to Gyra Systems, Inc., having its principal place of business in La Mesa, CA. The fields of use may be limited to package monitoring quality sensors to detect changes in product quality and authenticity, such as pharmaceutical, food, beverage, tobacco, and cosmetics products and/or similar field(s) of use thereto. NASA has not yet made a determination to grant the requested license and may deny the requested license even if no objections are submitted within the comment period.
Applications for New Awards; Alaska Native and Native Hawaiian-Serving Institutions Program
Document Number: 2020-01711
Type: Notice
Date: 2020-01-30
Agency: Department of Education
The Department of Education (Department) is issuing a notice inviting applications for new awards for fiscal year (FY) 2020 for the Alaska Native and Native Hawaiian-Serving Institutions (ANNH) Program, Catalog of Federal Domestic Assistance (CFDA) numbers 84.031N (Alaska Native) and 84.031W (Native Hawaiian). This notice relates to the approved information collection under OMB control number 1840-0810.
Long Term Follow-Up After Administration of Human Gene Therapy Products; Guidance for Industry; Availability
Document Number: 2020-01710
Type: Notice
Date: 2020-01-30
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance entitled ``Long Term Follow-Up After Administration of Human Gene Therapy Products.'' The guidance document provides sponsors, who are developing a human gene therapy (GT) product, recommendations regarding the design of long term follow- up (LTFU) observational studies for the collection of data on delayed adverse events following administration of a GT product. This guidance finalizes the draft guidance of the same title dated July 2018 and supersedes the document entitled ``Guidance for Industry: Gene Therapy Clinical TrialsObserving Subjects for Delayed Adverse Events'' dated November 2006. This guidance also supplements the guidance entitled ``Testing of Retroviral Vector-Based Human Gene Therapy Products for Replication Competent Retrovirus during Product Manufacture and Patient Follow-up; Guidance for Industry.''
Supplemental Environmental Impact Statement for the Arrow Canyon Solar Project on the Moapa River Indian Reservation, Clark County, Nevada
Document Number: 2020-01708
Type: Notice
Date: 2020-01-30
Agency: Department of the Interior, Bureau of Indian Affairs
The Bureau of Indian Affairs (BIA), as lead agency in cooperation with the Moapa Band of Paiute Indians (Moapa Band) and other agencies, intends to prepare a Supplemental Environmental Impact Statement (SEIS) that will evaluate the expansion of the previously approved Moapa Solar Energy Center (MSEC) Project on the Moapa River Indian Reservation (Reservation). This project is now referred to as the Arrow Canyon Solar Project (Project) and this notice announces the beginning of the scoping process to solicit public comments and identify potential issues related to the expansion. It also announces that two public scoping meetings will be held in Nevada to identify potential issues, alternatives, and mitigation to be considered in the SEIS.
Indian Entities Recognized by and Eligible To Receive Services From the United States Bureau of Indian Affairs
Document Number: 2020-01707
Type: Notice
Date: 2020-01-30
Agency: Department of the Interior, Bureau of Indian Affairs
This notice publishes the current list of 574 Tribal entities recognized by and eligible for funding and services from the Bureau of Indian Affairs (BIA) by virtue of their status as Indian Tribes. The list is updated from the notice published on February 1, 2019 (84 FR 1200).
Interpreting Sameness of Gene Therapy Products Under the Orphan Drug Regulations; Draft Guidance for Industry; Availability
Document Number: 2020-01705
Type: Notice
Date: 2020-01-30
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft document entitled ``Interpreting Sameness of Gene Therapy Products Under the Orphan Drug Regulations.'' The draft guidance document provides FDA's current thinking on the criteria to determine sameness of human gene therapy products for the purpose of orphan drug designation and orphan drug exclusivity. The draft guidance is intended to assist stakeholders, including industry and academic sponsors who seek orphan drug designation and orphan drug exclusivity, in the development of gene therapies for rare diseases.
Human Gene Therapy for Rare Diseases; Guidance for Industry; Availability
Document Number: 2020-01704
Type: Notice
Date: 2020-01-30
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance entitled ``Human Gene Therapy for Rare Diseases; Guidance for Industry.'' The final guidance document provides recommendations to stakeholders developing a human gene therapy (GT) product intended to treat a rare disease in adult and/or pediatric patients regarding the manufacturing, preclinical, and clinical trial design issues for all phases of the clinical development program. Such information is intended to assist sponsors in designing clinical development programs for such products, where there may be limited study population size and potential feasibility and safety issues as well as issues relating to the interpretability of bioactivity/efficacy outcomes that may be unique to rare diseases or to the nature of the GT product itself. The guidance announced in this notice finalizes the draft guidance of the same title dated July 2018.
Human Gene Therapy for Retinal Disorders; Guidance for Industry; Availability
Document Number: 2020-01703
Type: Notice
Date: 2020-01-30
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration is announcing the availability of a final guidance entitled ``Human Gene Therapy for Retinal Disorders; Guidance for Industry.'' The final guidance provides recommendations to stakeholders developing human gene therapy (GT) products for retinal disorders affecting adult and pediatric patients. The guidance focuses on issues specific to GT products for retinal disorders and provides recommendations related to product development, preclinical testing, and clinical trial design for such GT products. The guidance announced in this notice finalizes the draft guidance of the same title dated July 2018.
Human Gene Therapy for Hemophilia; Guidance for Industry; Availability
Document Number: 2020-01702
Type: Notice
Date: 2020-01-30
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance entitled ``Human Gene Therapy for Hemophilia; Guidance for Industry.'' The guidance document provides recommendations to stakeholders developing human gene therapy (GT) products for the treatment of hemophilia. The guidance provides recommendations on the clinical trial design and related development of coagulation factor VIII (hemophilia A) and IX (hemophilia B) activity assays, including how to address discrepancies in factor VIII and factor IX activity assays. The guidance also includes recommendations regarding preclinical considerations to support development of GT products for the treatment of hemophilia. The guidance announced in this notice finalizes the draft guidance of the same title dated July 2018.
Chemistry, Manufacturing, and Control Information for Human Gene Therapy Investigational New Drug Applications; Guidance for Industry; Availability
Document Number: 2020-01701
Type: Notice
Date: 2020-01-30
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance entitled ``Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs); Guidance for Industry.'' The guidance document provides sponsors of human gene therapy INDs with recommendations regarding CMC information to be submitted in an IND. The guidance document informs sponsors how to provide sufficient CMC information required to assure product safety, identity, quality, purity, and strength (including potency) of the investigational product. The guidance applies to human gene therapy products and to combination products that contain a human gene therapy in combination with a drug or device. The guidance announced in this notice finalizes the draft guidance of the same title dated July 2018 and supersedes the document entitled ``Guidance for FDA Reviewers and Sponsors: Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs),'' dated April 2008 (April 2008 guidance).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.